Skip to main content

Table 2 Cardiac diagnostics, therapies and survival data after propensity score matching

From: Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias

Characteristic No statin
(n = 212; 50%)
statin
(n = 212; 50%)
p value
Left ventricular ejection function, n (%)
 LVEF ≥55% 63 (30) 60 (28) 0.352
 LVEF 54–35% 63 (30) 62 (29)
 LVEF < 35% 86 (41) 90 (43)
Cardiac therapies at index, n (%)
 Cardiopulmonary resuscitation 61 (29) 51 (24) 0.271
  In hospital 26 (12) 21 (10) 0.439
  Out of hospital 35 (17) 30 (14) 0.500
 External defibrillation 59 (28) 51 (24) 0.375
 External cardioversion 13 (6) 9 (4) 0.381
 Systemic thrombolysis 7 (3) 5 (2) 0.558
 Targeted temperature management (TTM) 5 (2) 8 (4) 0.398
Coronary artery disease, n (%)
 Coronary angiography, overall 131 (62) 140 (66) 0.363
 Coronary artery disease, n (%)
  No evidence of CAD 47 (36) 41 (29) 0.425
  1-vessel 24 (18) 33 (24)
  2-vessel 27 (21) 24 (17)
  3-vessel 33 (25) 42 (30)
 CTO 32 (24) 27 (19) 0.305
 Presence of CABG 15 (12) 30 (21) 0.027
 Intracoronary thrombus 2 (2) 6 (4) 0.180
 CPR during coronary angiography 4 (3) 3 (2) 0.715
PCI, n (%) 28 (21) 43 (31) 0.081
Target lesions
 RCA 11 (5) 16 (8) 0.320
 LMT 1 (0.5) 0 (0) 1.000
 LAD 15 (7) 18 (9) 0.587
 RIM 0 (0) 0 (0)
 LCX 6 (3) 12 (6) 0.148
 Bypass graft 0 (0) 3 (1) 0.248
Electrical therapies at index, n (%)
 Electrophysiological examination 72 (34) 88 (42) 0.109
 Catheter ablation 18 (9) 19 (9) 0.863
Newly implanted devices at index, n (%)
 ICD 54 (26) 54 (26) 1.000
 CRT-D 3 (1) 8 (4) 0.127
 CRT-P 1 (0.5) 0 (0) 1.000
 Pacemaker 4 (2) 2 (0.9) 0.685
 Cardiac contractility modulation (CCM) 0 (0) 0 (0)
 Subcutaneous ICD 0 (0) 1 (0.9) 1.000
 Overall implanted devices 124 (59) 121 (57) 0.768
Medication at discharge, n (%)
Beta-blocker 162 (76) 187 (88) 0.001
 ACE-inhibitor 115 (54) 153 (72) 0.001
 AT1-Antagonist 21 (10) 29 (14) 0.249
 Aldosteron-antagonist 22 (10) 33 (16) 0.112
 Aspirin only 58 (27) 78 (37) 0.037
 Thienopyridine only 4 (2) 10 (5) 0.103
 Dual antiplatelet therapy 25 (12) 52 (25) 0.001
 Vitamin k antagonist 54 (26) 48 (23) 0.495
 NOAC 7 (3) 2 (0.9) 0.175
 Amiodarone 54 (26) 38 (18) 0.059
 Digitalis 33 (16) 38 (18) 0.515
Hospitalization time, days, (median (IQR))
 Total hospitalization time 16 (8–27) 14 (8–26) 0.009
 ICU time 3 (0–11) 2 (0–7) 0.004
 Follow-up time, days, (mean; median (range)) 1849; 1806
(25–5095)
1853; 1675
(18–5091)
0.013
All cause-mortality at 3 years, n (%) 70 (33) 33 (16) 0.001
  1. CABG; coronary artery bypass grafting; CAD, coronary artery disease; CRT-D, cardiac resynchronization therapy plus defibrillator; CRT-P, cardiac resynchronization therapy plus pacemaker; CTO, chronic total occlusion; LAD, left anterior descending; LCX, left circumflex; LVEF, left ventricular ejection function; ICD, implantable cardioverter-defibrillator; ICU, intensive care unit; IQR, interquartile range; NOAC, new oral anticoagulants; PCI, percutaneous coronary intervention; RCA, right coronary artery; RIM, Ramus intermedius. Bold type indicates p < 0.05